{"nctId":"NCT01530243","briefTitle":"The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms","startDateStruct":{"date":"2012-01"},"conditions":["Disorder of Urinary Stent"],"count":104,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Terazosin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Terazosine"]},{"label":"Tolterodine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tolterodine"]},{"label":"Tolterodine + Terazosin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tolterodine + Terazosin"]}],"interventions":[{"name":"Placebo","otherNames":["Group 1"]},{"name":"Terazosine","otherNames":["Group 2"]},{"name":"Tolterodine","otherNames":["Group 3"]},{"name":"Tolterodine + Terazosin","otherNames":["Group 4"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nIf a patient does not meet any exclusion criteria and to be undergone double-J stent indwelling.\n\nExclusion Criteria:\n\n1. Prior history of pelvic surgery\n2. Prior history of Transurethral Resection of the either Prostate or Bladder Tumor\n3. Benign prostate hyperplasia\n4. Recent or recurrent urinary tract infection\n5. Chronic medication with beta-blockers or Anti-cholinergic\n6. Pregnancy\n7. Prostatitis\n8. Prostate cancer\n9. Bilateral ureteroscopy or ureteral stenting\n10. Age \\< 18 and \\> 55\n11. Stone size \\> 20 mm\n12. Diabetes\n13. Bladder Outlet Obstruction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lower Urinary Tract Symptoms (LUTS)","description":"LUTS was evaluated using the International Prostate Symptom Score (IPSS) questionnaire perioperatively. The IPSS constitutes of seven questions assigned score from 0 to 5 to evaluate the severity of LUTS in patients. Total scoring of IPSS ranges from 0 to 35, asymptomatic to very symptomatic. The more the score on scale is, the worse the outcome is.Therefore, the higher values represent worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.12","spread":"7.84"},{"groupId":"OG001","value":"4.39","spread":"6.03"},{"groupId":"OG002","value":"7.21","spread":"6.57"},{"groupId":"OG003","value":"5.58","spread":"4.82"}]}]}]},{"type":"SECONDARY","title":"Quality of Life","description":"The Quality of life of patients was evaluated using single question in IPSS questionnaire in which each of patients received scoring from 0 to 6. The higher values represent the worse quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"2.16"},{"groupId":"OG001","value":"2","spread":"2.25"},{"groupId":"OG002","value":"2.30","spread":"1.89"},{"groupId":"OG003","value":"0.95","spread":"1.12"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pain","description":"The visual analogue scale (VAS) was used to evaluate the pain at the time of voiding. This VAS scoring ranges from 0 to 10. The higher values represent worse outcomes, having more pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.16","spread":"3.59"},{"groupId":"OG001","value":"3.21","spread":"4.14"},{"groupId":"OG002","value":"1.34","spread":"2.60"},{"groupId":"OG003","value":"1.37","spread":"2.56"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":24},"commonTop":[]}}}